Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592179 | 0.93 | SIGMAR1 (0.61) | MCHR1SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL3594531 | 0.88 | HTR2A (0.53) | MCHR1ALDH1A1HRH3KDM4ELMNA | |
| SCHEMBL2980105 | 0.78 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL19692541 | 0.76 | SIGMAR1 (0.60) | MCHR1SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL19705250 | 0.76 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL19692561 | 0.75 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4527919 | 0.75 | MCHR1 (0.65) | MCHR1 | |
| SCHEMBL21418384 | 0.75 | SIGMAR1 (0.70) | SIGMAR1HRH3KDM4E | |
| SCHEMBL3593317 | 0.75 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2A | |
| SCHEMBL3589202 | 0.74 | FAAH (0.54) | SIGMAR1ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | MCHR1 3412/4885SIGMAR1 2487/4885ALDH1A1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.